AlphAIAlphAI — Financial news for AI agents
investing.comOCT 231 min read$ABT

StoneX reiterates Buy on Abbott Labs stock, $120 target unchanged

StoneX reiterated a Buy rating and $120 target for Abbott Labs (ABT) after Q3 results. Abbott lowered its full-year revenue guidance to 6% and adjusted EPS to $5.50-$5.55. StoneX reduced its 2026 and 2027 revenue and EPS estimates. Abbott's Q3 revenue was $13.01B, up 7%, with adjusted EPS of $1.42. The company plans to spin off its Nutrition business by 2027. Analysts have mixed reactions to the guidance changes.

Original reporting
investing.com
Published Oct 23, 2026, 2:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 3:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ABT
Bearish
high confidence
Mentioned
$ABT
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ABTBearishMed
01

Why it matters

Guidance cuts signal slower growth, potentially pressuring the stock despite a positive rating.

02

Market read

Guidance revisions for a $177 B market‑cap health company are material for equity traders and sector positioning.

03

What to watch

Spin‑off of Nutrition business may unlock value and offset guidance concerns.

Relevance 7/10Novelty 7/10Timing: post‑earnings release today

Background

StoneX analyst reiterates a Buy on Abbott Laboratories after the company reported Q3 results and lowered its full‑year guidance.

Company-level read

Ticker impact

$ABTBearishHigh confidence
Context

StoneX cut Abbott's full-year revenue and EPS guidance and reiterated a Buy rating with a $120 target.

Expected impact

likely pressure as the market prices in the lower revenue and earnings outlook

Evidence & confidence

Guidance cuts for a large-cap health company typically trigger sell‑offs despite a Buy rating.

Market effects

Sector

May weigh on broader healthcare sector as peers' forecasts could be re‑examined.

Regional

U.S. market could see modest pullback in health‑care indices.

Global

Limited to investors tracking large‑cap pharma/health stocks.

Counterpoint

What could challenge this read

Buy rating and unchanged $120 target could support a short‑term bounce if the market overreacts.

Key entities

  • company
    Abbott Laboratories

    Large‑cap healthcare firm reporting Q3 2026 results.

  • analyst
    StoneX

    Equity research firm providing the rating and target.

Read at source← All news

Related articles

OCT 23
$ABTMedAI 8/10

Abbott’s colorectal cancer test shows improved sensitivity

Abbott (NYSE: ABT) presented data at the European Society for Medical Oncology Congress showing its Oncodetect test for colorectal cancer recurrence achieved 72.2% sensitivity, outperforming its previous version. The study analyzed 279 patients, detecting additional cases with the new test. Patients with detectable ctDNA had higher recurrence risk and lower survival rates. The test is not FDA-approved and is performed at Genomic Health Inc.

investing.com2 min
OCT 23
$ABTMedAI 8/10

Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer

Abbott (NYSE: ABT) presented data at ESMO 2026 showing its Oncodetect® test improved sensitivity for detecting colorectal cancer recurrence by 30% compared to its previous test. The study found a 10.6-fold higher recurrence risk for patients with detectable ctDNA. Abbott aims to connect innovations across cancer care, from early detection to post-treatment monitoring.

prnewswire.com2 min
OCT 22
$ABTMed

ABT Maintained by RBC Capital -- Price Target Lowered to $125

RBC Capital maintained an 'Outperform' rating on Abbott Laboratories (ABT) but lowered its price target from $130 to $125. GuruFocus values ABT at $135.74, suggesting a 24.9% undervaluation. The company has a GF Score of 82/100, indicating strong financial health and growth potential, but insiders have sold $46.85M in shares over the past three months.

gurufocus.com2 min
OCT 22
$ABTMed

Abbott plans nutrition spinoff as Q3 sales improve

Abbott plans to spin off its nutrition division by the end of 2027. Q3 sales improved 5.1% to $2.26B, but YTD sales fell 1.3%. The new company will include brands like Ensure and Similac, with 16,000 employees. Abbott's CEO cited changing consumer preferences as a driver for the separation.

nutraingredients.com2 min